The Washington Post

Beware the risks of ‘wellness’ peptides

CNBC

Samsung Biologics makes $1.8 billion all-cash offer for Switzerland's PolyPeptide Group

Financial Times

Samsung Biologics buys Swiss peptide maker for $1.8bn

The Chosun Daily

Samsung Biologics Acquires Swiss CDMO, Enters Obesity Drug Market

PolyPeptide

Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share

Samsung Biologics

Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India

Bloomberg

Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal

Metaculus

Glp 1 Based Drug Approval By 2029

Samsung Biologics announced on July 20, 2026, an all-cash public tender offer to acquire Switzerland's PolyPeptide Group AG for CHF 44.31 per share, valuing the company's equity at approximately CHF 1.46 billion ($1.8 billion).

Samsung Biologics announced on July 20, 2026, an all-cash public tender offer to acquire Switzerland's PolyPeptide Group AG for CHF 44.31 per share, valuing the company's equity at approximately CHF 1.46 billion ($1.8 billion).

The offer price represents a 40% premium to PolyPeptide's undisturbed share price of CHF 31.65, recorded on April 10, 2026 — the last trading day before market rumors of a potential acquisition emerged.

The offer price represents a 40% premium to PolyPeptide's undisturbed share price of CHF 31.65, recorded on April 10, 2026 — the last trading day before market rumors of a potential acquisition emerged.

PolyPeptide's board unanimously recommended the offer, and its largest shareholder, Draupnir Holding B.V., which holds approximately 55.65% of outstanding shares, committed to tender all of its shares into the offer.

PolyPeptide's board unanimously recommended the offer, and its largest shareholder, Draupnir Holding B.V., which holds approximately 55.65% of outstanding shares, committed to tender all of its shares into the offer.

Samsung Biologics said the deal marks the largest M&A transaction in South Korea's biopharmaceutical sector. South Korean outbound M&A rose 45% to $11.6 billion in the first half of this year compared with the same period in 2025, according to Dealogic.

Samsung Biologics said the deal marks the largest M&A transaction in South Korea's biopharmaceutical sector. South Korean outbound M&A rose 45% to $11.6 billion in the first half of this year compared with the same period in 2025, according to Dealogic.

PolyPeptide, founded in 1996 as a spinoff from pharmaceutical company Ferring, operates six production and research facilities across Sweden, Belgium, France, the U.S. and India, employing approximately 1,500 people and having produced over 1,000 therapeutic peptides.

PolyPeptide, founded in 1996 as a spinoff from pharmaceutical company Ferring, operates six production and research facilities across Sweden, Belgium, France, the U.S. and India, employing approximately 1,500 people and having produced over 1,000 therapeutic peptides.

PolyPeptide reported H1 2026 revenue of EUR 236.6 million, up 41.6% year-over-year, with metabolic therapeutics representing approximately 68% of total revenue. The transaction is expected to close by the end of 2026, subject to regulatory approvals and a minimum acceptance threshold of 66%.

PolyPeptide reported H1 2026 revenue of EUR 236.6 million, up 41.6% year-over-year, with metabolic therapeutics representing approximately 68% of total revenue. The transaction is expected to close by the end of 2026, subject to regulatory approvals and a minimum acceptance threshold of 66%.

The Washington Post #

CNBC #

Financial Times #

The Chosun Daily #

PolyPeptide #

Samsung Biologics #

Bloomberg #

Metaculus #

Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group

Health

Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group

Samsung Biologics makes $1.8 billion all-cash offer for Switzerland’s PolyPeptide Group

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters